To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 7854 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 7854 To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 5, 2026 Ms. Tlaib (for herself, Ms. Lee of Pennsylvania, and Mrs. Cherfilus- McCormick) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Medicines for the People Act''. SEC. 2. ESTABLISHMENT. (a) In General.--Part C of title IV of the Public Health Service Act (42 U.S.C. 285 et seq.) is amended by adding at the end the following: ``Subpart 21--National Institute for Biomedical Research and Development ``SEC. 464Z-11. PURPOSE AND FUNCTIONS OF INSTITUTE. ``(a) In General.--The general purposes of the National Institute for Biomedical Research and Development (referred to in this subpart as the `Institute') are-- ``(1) to engage in full-cycle development of drugs, devices, and biological products to promote long-term access to medicines, foster innovation, and ensure prioritization of public health needs; and ``(2) to make such drugs, devices, and biological products available to the public at equitable and accessible prices. ``(b) Re